UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 451

Sortiert nach

Taking gene-expression profiling to the clinic: when will molecular signatures become relevant to patient care?

Nature reviews. Cancer, 2007-07, Vol.7 (7), p.545-553

2007

Volltextzugriff (PDF)

Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers

Journal of clinical oncology, 2019-03, Vol.37 (7), p.559-569

2019

Volltextzugriff (PDF)

11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial

The Lancet (British edition), 2017-03, Vol.389 (10075), p.1195-1205

2017

Volltextzugriff (PDF)

Prognostic and Predictive Value of Tumor-Infiltrating Lymphocytes in a Phase III Randomized Adjuvant Breast Cancer Trial in Node-Positive Breast Cancer Comparing the Addition of Docetaxel to Doxorubicin With Doxorubicin-Based Chemotherapy: BIG 02-98

Journal of clinical oncology, 2013-03, Vol.31 (7), p.860-867

2013

Volltextzugriff (PDF)

Elucidating Prognosis and Biology of Breast Cancer Arising in Young Women Using Gene Expression Profiling

Clinical cancer research, 2012-03, Vol.18 (5), p.1341-1351

2012

Volltextzugriff (PDF)

Prognostic Impact of Pregnancy After Breast Cancer According to Estrogen Receptor Status: A Multicenter Retrospective Study

Journal of clinical oncology, 2013-01, Vol.31 (1), p.73-79

2013

Volltextzugriff (PDF)

PIK3CA genotype and a PIK3CA mutation-related gene signature and response to everolimus and letrozole in estrogen receptor positive breast cancer

PloS one, 2013-01, Vol.8 (1), p.e53292-e53292

2013

Volltextzugriff (PDF)

Phase III Study Comparing Exemestane With Tamoxifen As First-Line Hormonal Treatment of Metastatic Breast Cancer in Postmenopausal Women: The European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group

Journal of clinical oncology, 2008-10, Vol.26 (30), p.4883-4890

2008

Volltextzugriff (PDF)

Mechanisms of resistance to trastuzumab emtansine (T-DM1) in HER2-positive breast cancer

British journal of cancer, 2020-03, Vol.122 (5), p.603-612

2020

Volltextzugriff (PDF)

PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor—positive breast cancer

Proceedings of the National Academy of Sciences - PNAS, 2010-06, Vol.107 (22), p.10208-10213

2010

Volltextzugriff (PDF)

Definition of Clinically Distinct Molecular Subtypes in Estrogen Receptor–Positive Breast Carcinomas Through Genomic Grade

Journal of clinical oncology, 2007-04, Vol.25 (10), p.1239-1246

2007

Volltextzugriff (PDF)

Strong Time Dependence of the 76-Gene Prognostic Signature for Node-Negative Breast Cancer Patients in the TRANSBIG Multicenter Independent Validation Series

Clinical cancer research, 2007-06, Vol.13 (11), p.3207-3214

2007

Volltextzugriff (PDF)

Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer

Cancer treatment reviews, 2013-12, Vol.39 (8), p.935-946

2013

Volltextzugriff (PDF)

Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen

BMC genomics, 2008-05, Vol.9 (1), p.239-239, Article 239

2008

Volltextzugriff (PDF)

Randomized Trial of Letrozole Following Tamoxifen as Extended Adjuvant Therapy in Receptor-Positive Breast Cancer: Updated Findings from NCIC CTG MA.17

JNCI : Journal of the National Cancer Institute, 2005-09, Vol.97 (17), p.1262-1271

2005

Volltextzugriff (PDF)

A Randomized Trial of Letrozole in Postmenopausal Women after Five Years of Tamoxifen Therapy for Early-Stage Breast Cancer

The New England journal of medicine, 2003-11, Vol.349 (19), p.1793-1802

2003

Volltextzugriff (PDF)

Clinical Application of the 70-Gene Profile: The MINDACT Trial

Journal of clinical oncology, 2008-02, Vol.26 (5), p.729-735

2008

Volltextzugriff (PDF)

Late Extended Adjuvant Treatment With Letrozole Improves Outcome in Women With Early-Stage Breast Cancer Who Complete 5 Years of Tamoxifen

Journal of clinical oncology, 2008-04, Vol.26 (12), p.1948-1955

2008

Volltextzugriff (PDF)

Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer

NPJ breast cancer, 2022-08, Vol.8 (1), p.98-10, Article 98

2022

Volltextzugriff (PDF)

Trastuzumab-Associated Cardiac Events at 8 Years of Median Follow-Up in the Herceptin Adjuvant Trial (BIG 1-01)

Journal of clinical oncology, 2014-07, Vol.32 (20), p.2159-2165

2014

Volltextzugriff (PDF)

Opinion: Taking gene-expression profiling to the clinic: when will molecular signatures become relevant to patient care?

Nature reviews. Cancer, 2007-07, Vol.7 (7), p.545-553

2007

Volltextzugriff (PDF)

Correction: PIK3CA Genotype and a PIK3CA Mutation-Related Gene Signature and Response to Everolimus and Letrozole in Estrogen Receptor Positive Breast Cancer

PloS one, 2019-04, Vol.14 (4), p.e0216175-e0216175

2019

Volltextzugriff (PDF)

Efficacy, Toxicity, and Quality of Life in Older Women With Early-Stage Breast Cancer Treated With Letrozole or Placebo After 5 Years of Tamoxifen: NCIC CTG Intergroup Trial MA.17

Journal of clinical oncology, 2008-04, Vol.26 (12), p.1956-1964

2008

Volltextzugriff (PDF)

Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer

The New England journal of medicine, 2021-04, Vol.384 (16), p.1529-1541

2021

Volltextzugriff (PDF)

1 – 25 von 451

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(384)
Mit Volltextzugriff
(397)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Oncology
(261)
Humans
(240)
Science & Technology
(239)
Life Sciences & Biomedicine
(237)
Female
(223)
Breast Cancer
(173)
Breast Neoplasms - Drug Therapy
(152)
Middle Aged
(99)
Biological And Medical Sciences
(85)
Medical Sciences
(85)
Breast Neoplasms - Pathology
(82)
Tumors
(81)
Aged
(77)
Adult
(75)
Chemotherapy, Adjuvant
(71)
Chemotherapy
(64)
Breast Neoplasms - Genetics
(58)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(56)
Disease-Free Survival
(54)
Treatment Outcome
(51)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Taking gene-expression profiling to the clinic: when will molecular signatures become relevant to patient care?

Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers

11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial

Prognostic and Predictive Value of Tumor-Infiltrating Lymphocytes in a Phase III Randomized Adjuvant Breast Cancer Trial in Node-Positive Breast Cancer Comparing the Addition of Docetaxel to Doxorubicin With Doxorubicin-Based Chemotherapy: BIG 02-98

Elucidating Prognosis and Biology of Breast Cancer Arising in Young Women Using Gene Expression Profiling

Prognostic Impact of Pregnancy After Breast Cancer According to Estrogen Receptor Status: A Multicenter Retrospective Study

PIK3CA genotype and a PIK3CA mutation-related gene signature and response to everolimus and letrozole in estrogen receptor positive breast cancer

HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data

Phase III Study Comparing Exemestane With Tamoxifen As First-Line Hormonal Treatment of Metastatic Breast Cancer in Postmenopausal Women: The European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group

Mechanisms of resistance to trastuzumab emtansine (T-DM1) in HER2-positive breast cancer

PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor—positive breast cancer

Definition of Clinically Distinct Molecular Subtypes in Estrogen Receptor–Positive Breast Carcinomas Through Genomic Grade

Strong Time Dependence of the 76-Gene Prognostic Signature for Node-Negative Breast Cancer Patients in the TRANSBIG Multicenter Independent Validation Series

Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer

Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen

Randomized Trial of Letrozole Following Tamoxifen as Extended Adjuvant Therapy in Receptor-Positive Breast Cancer: Updated Findings from NCIC CTG MA.17

A Randomized Trial of Letrozole in Postmenopausal Women after Five Years of Tamoxifen Therapy for Early-Stage Breast Cancer

Clinical Application of the 70-Gene Profile: The MINDACT Trial

Late Extended Adjuvant Treatment With Letrozole Improves Outcome in Women With Early-Stage Breast Cancer Who Complete 5 Years of Tamoxifen

Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer

Trastuzumab-Associated Cardiac Events at 8 Years of Median Follow-Up in the Herceptin Adjuvant Trial (BIG 1-01)

Opinion: Taking gene-expression profiling to the clinic: when will molecular signatures become relevant to patient care?

Correction: PIK3CA Genotype and a PIK3CA Mutation-Related Gene Signature and Response to Everolimus and Letrozole in Estrogen Receptor Positive Breast Cancer

Efficacy, Toxicity, and Quality of Life in Older Women With Early-Stage Breast Cancer Treated With Letrozole or Placebo After 5 Years of Tamoxifen: NCIC CTG Intergroup Trial MA.17

Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer

Suchergebnisse filtern